We used a score ranging from 8.5 to 13 for a high probability of being a responder, because a PPV at 83.7% is nearly the response rate of targeted therapies, such as TKI in EGFR-mutated or ALK-rearranged NSCLC [17,18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.